PMID- 18043580
OWN - NLM
STAT- MEDLINE
DCOM- 20080214
LR  - 20211020
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 97
IP  - 12
DP  - 2007 Dec 17
TI  - Identification of Lck-derived peptides applicable to anti-cancer vaccine for 
      patients with human leukocyte antigen-A3 supertype alleles.
PG  - 1648-54
AB  - The identification of peptide vaccine candidates to date has been focused on 
      human leukocyte antigen (HLA)-A2 and -A24 alleles. In this study, we attempted to 
      identify cytotoxic T lymphocyte (CTL)-directed Lck-derived peptides applicable to 
      HLA-A11(+), -A31(+), or -A33(+) cancer patients, because these HLA-A alleles 
      share binding motifs, designated HLA-A3 supertype alleles, and because the Lck is 
      preferentially expressed in metastatic cancer. Twenty-one Lck-derived peptides 
      were prepared based on the binding motif to the HLA-A3 supertype alleles. They 
      were first screened for their recognisability by immunoglobulin G (IgG) in the 
      plasma of prostate cancer patients, and the selected candidates were subsequently 
      tested for their potential to induce peptide-specific CTLs from peripheral blood 
      mononuclear cells of HLA-A3 supertype(+) cancer patients. As a result, four Lck 
      peptides were frequently recognised by IgGs, and three of them - Lck(90-99), 
      Lck(449-458), and Lck(450-458) - efficiently induced peptide-specific and 
      cancer-reactive CTLs. Their cytotoxicity towards cancer cells was mainly ascribed 
      to HLA class I-restricted and peptide-specific CD8(+) T cells. These results 
      indicate that these three Lck peptides are applicable to HLA-A3 supertype(+) 
      cancer patients, especially those with metastasis. This information could 
      facilitate the development of peptide-based anti-cancer vaccine for patients with 
      alleles other than HLA-A2 and -A24.
FAU - Naito, M
AU  - Naito M
AD  - Department of Immunology, Kurume University School of Medicine, 67 Asahi-machi, 
      Kurume, Fukuoka 830-0011, Japan. haramano@med.shimane-u.ac.jp
FAU - Komohara, Y
AU  - Komohara Y
FAU - Ishihara, Y
AU  - Ishihara Y
FAU - Noguchi, M
AU  - Noguchi M
FAU - Yamashita, Y
AU  - Yamashita Y
FAU - Shirakusa, T
AU  - Shirakusa T
FAU - Yamada, A
AU  - Yamada A
FAU - Itoh, K
AU  - Itoh K
FAU - Harada, M
AU  - Harada M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071127
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA-A3 Antigen)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Peptides)
RN  - EC 2.7.10.2 (Lymphocyte Specific Protein Tyrosine Kinase p56(lck))
SB  - IM
MH  - Cancer Vaccines/*therapeutic use
MH  - Cell Line, Tumor
MH  - HLA-A3 Antigen/*genetics
MH  - Humans
MH  - Immunoglobulin G/analysis
MH  - Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/*immunology
MH  - Male
MH  - Neoplasms/genetics/immunology/*therapy
MH  - *Peptides
MH  - Prostatic Neoplasms/genetics/immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
PMC - PMC2360277
EDAT- 2007/11/29 09:00
MHDA- 2008/02/15 09:00
PMCR- 2008/12/17
CRDT- 2007/11/29 09:00
PHST- 2007/11/29 09:00 [pubmed]
PHST- 2008/02/15 09:00 [medline]
PHST- 2007/11/29 09:00 [entrez]
PHST- 2008/12/17 00:00 [pmc-release]
AID - 6604071 [pii]
AID - 10.1038/sj.bjc.6604071 [doi]
PST - ppublish
SO  - Br J Cancer. 2007 Dec 17;97(12):1648-54. doi: 10.1038/sj.bjc.6604071. Epub 2007 
      Nov 27.